Zimmer Biomet shares gained 2.5% after beating Q2 expectations and raising full-year guidance, though the stock continues to underperform the broader Nasdaq index on a 52-week basis.
Zimmer Biomet beat Q2 expectations and raised full-year guidance, but its stock has underperformed the Nasdaq over the past year, leaving a mixed outlook.
Penumbra is mentioned as a rival that lagged ZBH year-to-date but outperformed over 52 weeks, providing a comparative performance reference.
The Nasdaq Composite is used as the benchmark to compare Zimmer Biomet's stock performance, showing a 12.6% YTD gain and 17.2% 52-week return.
Zimmer Biomet reported a 4.8% increase in Q2 net sales to $2.18 billion and a 33.8% jump in EPS, prompting an upward revision of its full-year guidance. Despite this operational momentum, the stock remains a 'Hold' for many analysts as it continues to trail the Nasdaq Composite's 17.2% 52-week return.
Zimmer Biomet reported strong results with net sales rising 4.8% to $2.18 billion and EPS jumping 33.8% to $1.03, leading the company to raise its full-year guidance.